Cell Source is an immunotherapy and regenerative medicine company whose primary breakthrough is the regulation of immune tolerance. In preclinical studies Cell Source's therapies have demonstrated the ability to directly address a number of severe medical conditions including blood cancers such as non-Hodgkins lymphoma, multiple myeloma, and chronic lymphocytic leukemia. Cell Source's organ regeneration platform holds the potential to repair organs and to grow entire organs inside the patient's body. Growing or regenerating organs and using cell therapy to tolerize the immune system can each revolutionize the treatment of numerous severe diseases that today kill hundreds of thousands of patients annually.